2017
The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes
Knobf MT, Jeon S, Smith B, Harris L, Thompson S, Stacy MR, Insogna K, Sinusas AJ. The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes. Heart & Lung 2017, 46: 375-381. PMID: 28803675, PMCID: PMC6129386, DOI: 10.1016/j.hrtlng.2017.06.001.Peer-Reviewed Original ResearchConceptsFemale cancer survivorsCancer survivorsCenter interventionMET-minutes/weekStable insulin levelsMetabolic risk factorsResistance exercise programExercise stress testCardiovascular disease riskPhysical activity groupImproved insulin resistanceHeart rate recoveryMinutes/weekRisk reduction interventionsMajority of subjectsAdjuvant chemotherapyPremature menopauseExercise programInsulin levelsInsulin resistanceIntervention trialsRisk factorsCardiovascular functionBreast cancerRate recovery
2002
Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsBone and BonesBone ResorptionCollagenCollagen Type ICytokinesDisease Models, AnimalEstrogensFemaleFollow-Up StudiesHumansHyperparathyroidismInterleukin-6MenopauseMiceMiddle AgedOsteoporosis, PostmenopausalParathyroid HormonePeptidesPostmenopausePredictive Value of TestsPremenopauseReceptors, Interleukin-6Reference ValuesRetrospective StudiesConceptsIL-6/ILInterleukin-6Skeletal sensitivityPerimenopausal periodPrimary hyperparathyroidismPerimenopausal womenCytokine systemInterleukin-6 soluble receptorSerum IL-6 valuesEstrogen-deficient stateUrine N-telopeptideInterleukin-6/interleukinAction of PTHGroup of patientsIL-6 valuesSerum IL-6/ILEstrogen modulatesIL-6sRIL-6sR.Perimenopausal groupUrine NTXPremenopausal womenSkeletal complicationsCytokine profileExaggerated releaseTreatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients
1994
Dietary hypercalciuria in patients with calcium oxalate kidney stones
Burtis W, Gay L, Insogna K, Ellison A, Broadus A. Dietary hypercalciuria in patients with calcium oxalate kidney stones. American Journal Of Clinical Nutrition 1994, 60: 424-429. PMID: 8074077, DOI: 10.1093/ajcn/60.3.424.Peer-Reviewed Original ResearchConceptsCalcium excretionFree dietDietary hypercalciuriaKidney stonesUrinary calcium excretionHigh sodium intakeCalcium oxalate stonesHypercalciuric patientsSodium excretionUnselected patientsDietary sodiumSodium intakeDietary calciumDietary factorsDietary habitsPatientsHypercalciuriaExcretionOxalate stonesDietary proteinDietMultiple regression analysisCalciumStonesIntake